Microglial phenotypes in Parkinson's disease and animal models of the disease

Progress in Neurobiology

Volumn 155, Issue , 2017, Pages 57-75

  Joers, Valerie ^a   Tansey, Malú G ^a   Mulas, Giovanna ^b   Carta, Anna R ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Immune; Microglia; Neurodegeneration; Neuroinflammation; Neuroprotection; Parkinson's

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CANNABINOID 2 RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; LEUCINE RICH REPEAT KINASE 2; LIPOPOLYSACCHARIDE; MINOCYCLINE; OXIDOPAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; REGULATOR OF G PROTEIN SIGNALING 10 PROTEIN; RING FINGER PROTEIN; RING FINGER PROTEIN 11; UNCLASSIFIED DRUG;

ANIMAL MODEL; CELL ACTIVATION; DEGENERATION; GLIOSIS; HUMAN; INFLAMMATORY CELL; MICROGLIA; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; ANIMAL; DISEASE MODEL; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICROGLIA; PARKINSON DISEASE; PHENOTYPE;

EID: 84965079907     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2016.04.006     Document Type: Review

References (227)

1. Allen Reish, H.E., Standaert, D.G., Role of alpha-synuclein in inducing innate and adaptive immunity in parkinson disease. J. Parkinsons Dis. 5 (2015), 1–19.
2. Alliot, F., Godin, I., Pessac, B., Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res. Dev. Brain Res. 117 (1999), 145–152.
3. Arai, H., Furuya, T., Yasuda, T., Miura, M., Mizuno, Y., Mochizuki, H., Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J. Biol. Chem. 279 (2004), 51647–51653.
4. Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., Watada, H., Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59 (2010), 1030–1037.
5. Armentero, M.T., Levandis, G., Nappi, G., Bazzini, E., Blandini, F., Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol. Dis. 24 (2006), 492–505.
6. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123 (2013), 2730–2736.
7. Baiguera, C., Alghisi, M., Pinna, A., Bellucci, A., De Luca, M.A., Frau, L., Morelli, M., Ingrassia, R., Benarese, M., Porrini, V., et al. Late-onset parkinsonism in NFkappaB/c-Rel-deficient mice. Brain 135 (2012), 2750–2765.
8. Baldwin, A.S. Jr., Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 107 (2001), 3–6.
9. Ballesteros, I., Cuartero, M.I., Pradillo, J.M., de la Parra, J., Perez-Ruiz, A., Corbi, A., Ricote, M., Hamilton, J.A., Sobrado, M., Vivancos, J., et al. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARgamma and 5-LO-dependent pathways. J. Leukoc. Biol. 95 (2014), 587–598.
10. Banati, R.B., Myers, R., Kreutzberg, G.W., PK (‘peripheral benzodiazepine’)–binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J. Neurocytol. 26 (1997), 77–82.
11. Barcia, C., Sanchez Bahillo, A., Fernandez-Villalba, E., Bautista, V., Poza, Y.P.M., Fernandez-Barreiro, A., Hirsch, E.C., Herrero, M.T., Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46 (2004), 402–409.
12. Barcia, C., Ros, C.M., Annese, V., Gomez, A., Ros-Bernal, F., Aguado-Yera, D., Martinez-Pagan, M.E., de Pablos, V., Fernandez-Villalba, E., Herrero, M.T., IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis, 2, 2011, e142.
13. Barcia, C., Ros, C.M., Ros-Bernal, F., Gomez, A., Annese, V., Carrillo-de Sauvage, M.A., Yuste, J.E., Campuzano, C.M., de Pablos, V., Fernandez-Villalba, E., Herrero, M.T., Persistent phagocytic characteristics of microglia in the substantia nigra of long-term Parkinsonian macaques. J. Neuroimmunol. 261 (2013), 60–66.
14. Barkholt, P., Sanchez-Guajardo, V., Kirik, D., Romero-Ramos, M., Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience 208 (2012), 85–96.
15. Barnum, C.J., Eskow, K.L., Dupre, K., Blandino, P. Jr., Deak, T., Bishop, C., Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 156 (2008), 30–41.
16. Bartels, A.L., Willemsen, A.T., Doorduin, J., de Vries, E.F., Dierckx, R.A., Leenders, K.L., [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?. Parkinsonism Relat. Disord. 16 (2010), 57–59.
17. Baumeister, D., Ciufolini, S., Mondelli, V., Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?. Psychopharmacology (Berl.), 2015.
18. Bernardo, A., Levi, G., Minghetti, L., Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12 (2000), 2215–2223.
19. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H., Wikstrom, L., Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 326–338.
20. Bian, M.J., Li, L.M., Yu, M., Fei, J., Huang, F., Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice. Brain Res. 1302 (2009), 256–264.
21. Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11 (2010), 889–896.
22. Bliederhaeuser, C., Grozdanov, V., Speidel, A., Zondler, L., Ruf, W.P., Bayer, H., Kiechle, M., Feiler, M.S., Freischmidt, A., Brenner, D., et al. Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathol., 2015.
23. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., Riederer, P., Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202 (1995), 17–20.
24. Bonizzi, G., Karin, M., The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004), 280–288.
25. Bower, J.H., Maraganore, D.M., Peterson, B.J., Ahlskog, J.E., Rocca, W.A., Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67 (2006), 494–496.
26. Brodacki, B., Staszewski, J., Toczylowska, B., Kozlowska, E., Drela, N., Chalimoniuk, M., Stepien, A., Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 441 (2008), 158–162.
27. Buchsel, P.C., Forgey, A., Grape, F.B., Hamann, S.S., Granulocyte macrophage colony-stimulating factor: current practice and novel approaches. Clin. J. Oncol. Nurs. 6 (2002), 198–205.
28. Butovsky, O., Jedrychowski, M.P., Moore, C.S., Cialic, R., Lanser, A.J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P.M., Doykan, C.E., et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat. Neurosci. 17 (2014), 131–143.
29. Cardona, A.E., Pioro, E.P., Sasse, M.E., Kostenko, V., Cardona, S.M., Dijkstra, I.M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9 (2006), 917–924.
30. Carta, A.R., Simuni, T., Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs 24 (2015), 219–227.
31. Carta, A.R., Frau, L., Pisanu, A., Wardas, J., Spiga, S., Carboni, E., Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 194 (2011), 250–261.
32. Carta, A.R., PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr. Drug Targets 14 (2013), 743–751.
33. Castano, A., Herrera, A.J., Cano, J., Machado, A., Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70 (1998), 1584–1592.
34. Cebrian, C., Zucca, F.A., Mauri, P., Steinbeck, J.A., Studer, L., Scherzer, C.R., Kanter, E., Budhu, S., Mandelbaum, J., Vonsattel, J.P., et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun., 5, 2014, 3633.
35. Chen, H., Jacobs, E., Schwarzschild, M.A., McCullough, M.L., Calle, E.E., Thun, M.J., Ascherio, A., Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58 (2005), 963–967.
36. Chesselet, M.F., Richter, F., Zhu, C., Magen, I., Watson, M.B., Subramaniam, S.R., A progressive mouse model of Parkinson's disease: the Thy1-aSyn (Line 61) mice. Neurotherapeutics 9 (2012), 297–314.
37. Cho, B.P., Song, D.Y., Sugama, S., Shin, D.H., Shimizu, Y., Kim, S.S., Kim, Y.S., Joh, T.H., Pathological dynamics of activated microglia following medial forebrain bundle transection. Glia 53 (2006), 92–102.
38. Croisier, E., Moran, L.B., Dexter, D.T., Pearce, R.K., Graeber, M.B., Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J. Neuroinflammation, 2, 2005, 14.
39. Czlonkowska, A., Kohutnicka, M., Kurkowska-Jastrzebska, I., Czlonkowski, A., Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5 (1996), 137–143.
40. Daher, J.P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S., West, A.B., Abrogation of alpha-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 9289–9294.
41. Dalal, N.V., Pranski, E.L., Tansey, M.G., Lah, J.J., Levey, A.I., Betarbet, R.S., RNF11 modulates microglia activation through NF-kappaB signalling cascade. Neurosci. Lett. 528 (2012), 174–179.
42. Dawson, T.M., Ko, H.S., Dawson, V.L., Genetic animal models of Parkinson's disease. Neuron 66 (2010), 646–661.
43. De Lella Ezcurra, A.L., Chertoff, M., Ferrari, C., Graciarena, M., Pitossi, F., Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol. Dis. 37 (2010), 630–640.
44. Decressac, M., Mattsson, B., Lundblad, M., Weikop, P., Bjorklund, A., Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 45 (2012), 939–953.
45. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J., Schulz, J.B., Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88 (2004), 494–501.
46. Depino, A.M., Earl, C., Kaczmarczyk, E., Ferrari, C., Besedovsky, H., del Rey, A., Pitossi, F.J., Oertel, W.H., Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 18 (2003), 2731–2742.
47. Doorn, K.J., Breve, J.J., Drukarch, B., Boddeke, H.W., Huitinga, I., Lucassen, P.J., van Dam, A.M., Brain region-specific gene expression profiles in freshly isolated rat microglia. Front. Cell. Neurosci., 9, 2015, 84.
48. Du, Y., Ma, Z., Lin, S., Dodel, R.C., Gao, F., Bales, K.R., Triarhou, L.C., Chernet, E., Perry, K.W., Nelson, D.L., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 14669–14674.
49. Dutta, G., Zhang, P., Liu, B., The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol. 22 (2008), 453–464.
50. Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F.E., Brooks, D.J., Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 38 (2013), 938–949.
51. Edwards, J.P., Zhang, X., Frauwirth, K.A., Mosser, D.M., Biochemical and functional characterization of three activated macrophage populations. J. Leukoc. Biol. 80 (2006), 1298–1307.
52. Eslamboli, A., Romero-Ramos, M., Burger, C., Bjorklund, T., Muzyczka, N., Mandel, R.J., Baker, H., Ridley, R.M., Kirik, D., Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130 (2007), 799–815.
53. Esposito, E., Di Matteo, V., Benigno, A., Pierucci, M., Crescimanno, G., Di Giovanni, G., Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205 (2007), 295–312.
54. Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D.J., Edison, P., Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimers Dement. 11 (2015), 608–621 (e607).
55. Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G.K., Stefanova, N., Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 61 (2013), 349–360.
56. Ferger, B., Leng, A., Mura, A., Hengerer, B., Feldon, J., Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89 (2004), 822–833.
57. Flood, P.M., Qian, L., Peterson, L.J., Zhang, F., Shi, J.S., Gao, H.M., Hong, J.S., Transcriptional factor NF-kappaB as a target for therapy in Parkinson's disease. Parkinsons Dis., 2011, 2011, 216298.
58. Foltynie, T., Aviles-Olmos, I., Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic. Alzheimers Dement. 10 (2014), S38–46.
59. Fox, S.H., Henry, B., Hill, M., Crossman, A., Brotchie, J., Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 17 (2002), 1180–1187.
60. Frank-Cannon, T.C., Alto, L.T., McAlpine, F.E., Tansey, M.G., Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol. Neurodegener., 4, 2009, 47.
61. Gao, H.M., Jiang, J., Wilson, B., Zhang, W., Hong, J.S., Liu, B., Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002), 1285–1297.
62. Gao, H.M., Kotzbauer, P.T., Uryu, K., Leight, S., Trojanowski, J.Q., Lee, V.M., Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28 (2008), 7687–7698.
63. Gao, H.M., Zhang, F., Zhou, H., Kam, W., Wilson, B., Hong, J.S., Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ. Health Perspect. 119 (2011), 807–814.
64. Gao, X., Chen, H., Schwarzschild, M.A., Ascherio, A., Use of ibuprofen and risk of Parkinson disease. Neurology 76 (2011), 863–869.
65. Garcia-Esparcia, P., Llorens, F., Carmona, M., Ferrer, I., Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson's disease brain is region dependent. Brain Pathol. 24 (2014), 584–598.
66. Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R.B., Brooks, D.J., In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21 (2006), 404–412.
67. Ghosh, A., Roy, A., Liu, X., Kordower, J.H., Mufson, E.J., Hartley, D.M., Ghosh, S., Mosley, R.L., Gendelman, H.E., Pahan, K., Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 18754–18759.
68. Giasson, B.I., Ischiropoulos, H., Lee, V.M., Trojanowski, J.Q., The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic. Biol. Med. 32 (2002), 1264–1275.
69. Gillardon, F., Schmid, R., Draheim, H., Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208 (2012), 41–48.
70. Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodriguez de Fonseca, F., Navarro, M., Piomelli, D., Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2 (1999), 358–363.
71. Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140 (2010), 918–934.
72. Gomez-Galvez, Y., Palomo-Garo, C., Fernandez-Ruiz, J., Garcia, C., Potential of the cannabinoid CB receptor as a pharmacological target against inflammation in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2015.
73. Grabert, K., Michoel, T., Karavolos, M.H., Clohisey, S., Baillie, J.K., Stevens, M.P., Freeman, T.C., Summers, K.M., McColl, B.W., Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci., 2016.
74. Gratchev, A., Kzhyshkowska, J., Kannookadan, S., Ochsenreiter, M., Popova, A., Yu, X., Mamidi, S., Stonehouse-Usselmann, E., Muller-Molinet, I., Gooi, L., Goerdt, S., Activation of a TGF-beta-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-beta receptor II. J. Immunol. 180 (2008), 6553–6565.
75. Grinberg-Bleyer, Y., Dainichi, T., Oh, H., Heise, N., Klein, U., Schmid, R.M., Hayden, M.S., Ghosh, S., Cutting edge: nF-kappaB p65 and c-Rel control epidermal development and immune homeostasis in the skin. J. Immunol. 194 (2015), 2472–2476.
76. Hamza, T.H., Zabetian, C.P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D.M., Doheny, K.F., Paschall, J., Pugh, E., et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42 (2010), 781–785.
77. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S., Whitton, P.S., Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation, 5, 2008, 19.
78. Harms, A.S., Barnum, C.J., Ruhn, K.A., Varghese, S., Trevino, I., Blesch, A., Tansey, M.G., Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol. Ther. 19 (2011), 46–52.
79. Harms, A.S., Lee, J.K., Nguyen, T.A., Chang, J., Ruhn, K.M., Trevino, I., Tansey, M.G., Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 60 (2012), 189–202.
80. Hayden, M.S., Ghosh, S., Signaling to NF-kappaB. Genes Dev. 18 (2004), 2195–2224.
81. Healy, D.G., Wood, N.W., Schapira, A.H., Test for LRRK2 mutations in patients with Parkinson's disease. Pract. Neurol. 8 (2008), 381–385.
82. Heiman, M., Schaefer, A., Gong, S., Peterson, J.D., Day, M., Ramsey, K.E., Suarez-Farinas, M., Schwarz, C., Stephan, D.A., Surmeier, D.J., et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 135 (2008), 738–748.
83. Henry, V., Paille, V., Lelan, F., Brachet, P., Damier, P., Kinetics of microglial activation and degeneration of dopamine-containing neurons in a rat model of Parkinson disease induced by 6-hydroxydopamine. J. Neuropathol. Exp. Neurol. 68 (2009), 1092–1102.
84. Heppner, F.L., Ransohoff, R.M., Becher, B., Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16 (2015), 358–372.
85. Herrera, A.J., Castano, A., Venero, J.L., Cano, J., Machado, A., The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7 (2000), 429–447.
86. Hickman, S.E., Allison, E.K., El Khoury, J., Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28 (2008), 8354–8360.
87. Hoek, R.M., Ruuls, S.R., Murphy, C.A., Wright, G.J., Goddard, R., Zurawski, S.M., Blom, B., Homola, M.E., Streit, W.J., Brown, M.H., et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290 (2000), 1768–1771.
88. Hofmann, K.W., Schuh, A.F., Saute, J., Townsend, R., Fricke, D., Leke, R., Souza, D.O., Portela, L.V., Chaves, M.L., Rieder, C.R., Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem. Res. 34 (2009), 1401–1404.
89. Holscher, C., Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221 (2014), T31–41.
90. Hoozemans, J.J., Veerhuis, R., Rozemuller, J.M., Eikelenboom, P., Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int. J. Dev. Neurosci. 24 (2006), 157–165.
91. Hunot, S., Brugg, B., Ricard, D., Michel, P.P., Muriel, M.P., Ruberg, M., Faucheux, B.A., Agid, Y., Hirsch, E.C., Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 7531–7536.
92. Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., Tardieu, M., Debre, P., Agid, Y., Dugas, B., Hirsch, E.C., FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999), 3440–3447.
93. Hurley, S.D., O'Banion, M.K., Song, D.D., Arana, F.S., Olschowka, J.A., Haber, S.N., Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp. Neurol. 184 (2003), 659–668.
94. Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R.M., Perani, D., In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat. Disord. 19 (2013), 47–52.
95. Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., Hashizume, Y., Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106 (2003), 518–526.
96. Investigators, N.N.-P., A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006), 664–671.
97. Investigators, N.N.-P., A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 31 (2008), 141–150.
98. Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., Oka, J., Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci. Res. 55 (2006), 352–360.
99. Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., Vitorica, J., Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 28 (2008), 11650–11661.
100. Jyothi, H.J., Vidyadhara, D.J., Mahadevan, A., Philip, M., Parmar, S.K., Manohari, S.G., Shankar, S.K., Raju, T.R., Alladi, P.A., Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta. Neurobiol. Aging 36 (2015), 3321–3333.
101. Kannarkat, G.T., Cook, D.A., Lee, J.-K., Chang, J., Chung, J., Sandy, E., Factor, S.A., Boss, J.M., Tansey, M.G., Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson's disease: an observational and case–control study. Disease, 1, 2015, 10.1038/npjparkd.2015.2 Article number: 15002 (2015).
102. Kim, W.G., Mohney, R.P., Wilson, B., Jeohn, G.H., Liu, B., Hong, J.S., Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20 (2000), 6309–6316.
103. Kim, S., Moon, M., Park, S., Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202 (2009), 431–439.
104. Kim, B., Yang, M.S., Choi, D., Kim, J.H., Kim, H.S., Seol, W., Choi, S., Jou, I., Kim, E.Y., Joe, E.H., Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One, 7, 2012, e34693.
105. Knott, C., Stern, G., Wilkin, G.P., Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16 (2000), 724–739.
106. Kohutnicka, M., Lewandowska, E., Kurkowska-Jastrzebska, I., Czlonkowski, A., Czlonkowska, A., Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998), 167–180.
107. Koshimori, Y., Ko, J.H., Mizrahi, R., Rusjan, P., Mabrouk, R., Jacobs, M.F., Christopher, L., Hamani, C., Lang, A.E., Wilson, A.A., et al. Imaging striatal microglial activation in patients with Parkinson's disease. PLoS One, 10, 2015, e0138721.
108. Kosloski, L.M., Kosmacek, E.A., Olson, K.E., Mosley, R.L., Gendelman, H.E., GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J. Neuroimmunol. 265 (2013), 1–10.
109. Koziorowski, D., Tomasiuk, R., Szlufik, S., Friedman, A., Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 60 (2012), 762–766.
110. Krabbe, G., Halle, A., Matyash, V., Rinnenthal, J.L., Eom, G.D., Bernhardt, U., Miller, K.R., Prokop, S., Kettenmann, H., Heppner, F.L., Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One, 8, 2013, e60921.
111. Kurkowska-Jastrzebska, I., Wronska, A., Kohutnicka, M., Czlonkowski, A., Czlonkowska, A., The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156 (1999), 50–61.
112. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A., Karluk, D., Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999), 598–605.
113. Lawson, L.J., Perry, V.H., Dri, P., Gordon, S., Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39 (1990), 151–170.
114. Lecca, D., Nevin, D.K., Mulas, G., Casu, M.A., Diana, A., Rossi, D., Sacchetti, G., Carta, A.R., Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice. Neuroscience 302 (2015), 23–35.
115. Lee, J.K., McCoy, M.K., Harms, A.S., Ruhn, K.A., Gold, S.J., Tansey, M.G., Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J. Neurosci. 28 (2008), 8517–8528.
116. Lee, J.K., Chung, J., McAlpine, F.E., Tansey, M.G., Regulator of G-protein signaling-10 negatively regulates NF-kappaB in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats. J. Neurosci. 31 (2011), 11879–11888.
117. Lee, J.K., Chung, J., Kannarkat, G.T., Tansey, M.G., Critical role of regulator G-protein signaling 10 (RGS10) in modulating macrophage M1/M2 activation. PLoS One, 8, 2013, e81785.
118. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 1285–1290.
119. Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., Mandir, A.S., Vila, M., McAuliffe, W.G., Dawson, V.L., Dawson, T.M., Przedborski, S., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999), 1403–1409.
120. Lin, X., Parisiadou, L., Gu, X.L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.X., Yang, W.J., Ding, J., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64 (2009), 807–827.
121. Lindqvist, D., Hall, S., Surova, Y., Nielsen, H.M., Janelidze, S., Brundin, L., Hansson, O., Cerebrospinal fluid inflammatory markers in Parkinson's disease–associations with depression, fatigue, and cognitive impairment. Brain Behav. Immun. 33 (2013), 183–189.
122. Lo Bianco, C., Ridet, J.L., Schneider, B.L., Deglon, N., Aebischer, P., alpha −Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 10813–10818.
123. Lofrumento, D.D., Saponaro, C., Cianciulli, A., De Nuccio, F., Mitolo, V., Nicolardi, G., Panaro, M.A., MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 18 (2011), 79–88.
124. Luchtman, D.W., Shao, D., Song, C., Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 98 (2009), 130–138.
125. Mackaness, G.B., Cellular resistance to infection. J. Exp. Med. 116 (1962), 381–406.
126. Magen, I., Chesselet, M.F., Genetic mouse models of Parkinson's disease. The state of the art. Prog. Brain Res. 184 (2010), 53–87.
127. Maia, S., Arlicot, N., Vierron, E., Bodard, S., Vergote, J., Guilloteau, D., Chalon, S., Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse 66 (2012), 573–583.
128. Mangano, E.N., Peters, S., Litteljohn, D., So, R., Bethune, C., Bobyn, J., Clarke, M., Hayley, S., Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease. Neurobiol. Dis. 43 (2011), 99–112.
129. Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J.B., Medhurst, A.D., Dexter, D.T., Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J. Neurochem. 110 (2009), 966–975.
130. Marker, D.F., Puccini, J.M., Mockus, T.E., Barbieri, J., Lu, S.M., Gelbard, H.A., LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J. Neuroinflammation, 9, 2012, 261.
131. Martin, H.L., Mounsey, R.B., Mustafa, S., Sathe, K., Teismann, P., Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPARgamma) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp. Neurol. 235 (2012), 528–538.
132. Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000 Prime Rep., 6, 2014, 13.
133. Martinez, F.O., Gordon, S., Locati, M., Mantovani, A., Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177 (2006), 7303–7311.
134. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., Mucke, L., Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000), 1265–1269.
135. Mattson, M.P., Goodman, Y., Luo, H., Fu, W., Furukawa, K., Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J. Neurosci. Res. 49 (1997), 681–697.
136. May, M.J., D'Acquisto, F., Madge, L.A., Glockner, J., Pober, J.S., Ghosh, S., Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289 (2000), 1550–1554.
137. McCoy, M.K., Martinez, T.N., Ruhn, K.A., Szymkowski, D.E., Smith, C.G., Botterman, B.R., Tansey, K.E., Tansey, M.G., Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 26 (2006), 9365–9375.
138. McCoy, M.K., Ruhn, K.A., Martinez, T.N., McAlpine, F.E., Blesch, A., Tansey, M.G., Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol. Ther. 16 (2008), 1572–1579.
139. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988), 1285–1291.
140. McGeer, P.L., Schwab, C., Parent, A., Doudet, D., Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54 (2003), 599–604.
141. Melief, J., Koning, N., Schuurman, K.G., Van De Garde, M.D., Smolders, J., Hoek, R.M., Van Eijk, M., Hamann, J., Huitinga, I., Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia 60 (2012), 1506–1517.
142. Meredith, S.C., Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann. N. Y. Acad. Sci. 1066 (2005), 181–221.
143. Mesnage, V., Houeto, J.L., Bonnet, A.M., Clavier, I., Arnulf, I., Cattelin, F., Le Fur, G., Damier, P., Welter, M.L., Agid, Y., Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin. Neuropharmacol. 27 (2004), 108–110.
144. Mills, C.D., Kincaid, K., Alt, J.M., Heilman, M.J., Hill, A.M., M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164 (2000), 6166–6173.
145. Mittelbronn, M., Dietz, K., Schluesener, H.J., Meyermann, R., Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 101 (2001), 249–255.
146. Mittelbronn, M., The M1/M2 immune polarization concept in microglia: a fair transfer?. Neuroimmunol. Neuroinflammation, 1, 2014, 2.
147. Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., Cowell, R.M., West, A.B., LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32 (2012), 1602–1611.
148. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., Nagatsu, T., Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180 (1994), 147–150.
149. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., Nagatsu, T., Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994), 208–210.
150. Mogi, M., Harada, M., Kondo, T., Narabayashi, H., Riederer, P., Nagatsu, T., Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 193 (1995), 129–132.
151. Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., Nagatsu, T., Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211 (1996), 13–16.
152. Mogi, M., Kondo, T., Mizuno, Y., Nagatsu, T., p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci. Lett. 414 (2007), 94–97.
153. Mondal, S., Roy, A., Jana, A., Ghosh, S., Kordower, J.H., Pahan, K., Testing NF-kappaB-based therapy in hemiparkinsonian monkeys. J. Neuroimmune Pharmacol. 7 (2012), 544–556.
154. Moore, C.S., Ase, A.R., Kinsara, A., Rao, V.T., Michell-Robinson, M., Leong, S.Y., Butovsky, O., Ludwin, S.K., Seguela, P., Bar-Or, A., Antel, J.P., P2Y12 expression and function in alternatively activated human microglia. Neurol. Neuroimmunol. Neuroinflamm., 2, 2015, e80.
155. Morgese, M.G., Cassano, T., Cuomo, V., Giuffrida, A., Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 208 (2007), 110–119.
156. Muller, T., Blum-Degen, D., Przuntek, H., Kuhn, W., Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol. Scand. 98 (1998), 142–144.
157. Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., Gordon, S., Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20.
158. NETPD-Investigators, 2014 annual meetings. Ann. Neurol. 76:Suppl 18 (2014), S1–S254.
159. Nagatsu, T., Mogi, M., Ichinose, H., Togari, A., Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. Suppl., 2000, 277–290.
160. Nassar, N.N., Al-Shorbagy, M.Y., Arab, H.H., Abdallah, D.M., Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89 (2015), 308–317.
161. Nau, G.J., Richmond, J.F., Schlesinger, A., Jennings, E.G., Lander, E.S., Young, R.A., Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 1503–1508.
162. Noyce, A.J., Bestwick, J.P., Silveira-Moriyama, L., Hawkes, C.H., Giovannoni, G., Lees, A.J., Schrag, A., Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 72 (2012), 893–901.
163. O'Neill, L.A., Kaltschmidt, C., NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 20 (1997), 252–258.
164. Odegaard, J.I., Ricardo-Gonzalez, R.R., Goforth, M.H., Morel, C.R., Subramanian, V., Mukundan, L., Red Eagle, A., Vats, D., Brombacher, F., Ferrante, A.W., Chawla, A., Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447 (2007), 1116–1120.
165. Olah, M., Biber, K., Vinet, J., Boddeke, H.W., Microglia phenotype diversity. CNS Neurol. Disord. Drug Targets 10 (2011), 108–118.
166. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., Torizuka, T., Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57 (2005), 168–175.
167. Owen, D.R., Yeo, A.J., Gunn, R.N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D.J., Bennacef, I., Parker, C.A., et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J. Cereb. Blood Flow Metab. 32 (2012), 1–5.
168. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004), 595–600.
169. Panet, H., Barzilai, A., Daily, D., Melamed, E., Offen, D., Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J. Neurochem. 77 (2001), 391–398.
170. Papadopoulos, V., Baraldi, M., Guilarte, T.R., Knudsen, T.B., Lacapere, J.J., Lindemann, P., Norenberg, M.D., Nutt, D., Weizman, A., Zhang, M.R., Gavish, M., Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27 (2006), 402–409.
171. Pascual, G., Ricote, M., Hevener, A.L., Macrophage peroxisome proliferator activated receptor gamma as a therapeutic target to combat Type 2 diabetes. Expert Opin. Ther. Targets 11 (2007), 1503–1520.
172. Pattarini, R., Smeyne, R.J., Morgan, J.I., Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience 145 (2007), 654–668.
173. Penas, F., Mirkin, G.A., Hovsepian, E., Cevey, A., Caccuri, R., Sales, M.E., Goren, N.B., PPARγ ligand treatment inhibits cardiac inflammatory mediators induced by infection with different lethality strains of Trypanosoma cruzi. Biochim. Biophys. Acta 1832 (2013), 239–248.
174. Perego, C., Fumagalli, S., De Simoni, M.G., Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J. Neuroinflammation, 8, 2011, 174.
175. Perry, V.H., Holmes, C., Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 10 (2014), 217–224.
176. Perry, V.H., Cunningham, C., Holmes, C., Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7 (2007), 161–167.
177. Pisanu, A., Lecca, D., Mulas, G., Wardas, J., Simbula, G., Spiga, S., Carta, A.R., Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-gamma agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiol. Dis. 71 (2014), 280–291.
178. Pott Godoy, M.C., Tarelli, R., Ferrari, C.C., Sarchi, M.I., Pitossi, F.J., Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131 (2008), 1880–1894.
179. Pranski, E.L., Dalal, N.V., Sanford, C.V., Herskowitz, J.H., Gearing, M., Lazo, C., Miller, G.W., Lah, J.J., Levey, A.I., Betarbet, R.S., RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-kappaB signaling in dopaminergic cells. Neurobiol. Dis. 54 (2013), 264–279.
180. Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.S., Knapp, D.J., Crews, F.T., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55 (2007), 453–462.
181. Ramonet, D., Daher, J.P., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One, 6, 2011, e18568.
182. Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., Whitton, P., Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. Br. J. Pharmacol. 167 (2012), 1467–1479.
183. Ramsey, C.P., Tansey, M.G., A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets. Exp. Neurol. 256 (2014), 126–132.
184. Reddy, R.C., Narala, V.R., Keshamouni, V.G., Milam, J.E., Newstead, M.W., Standiford, T.J., Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}. Blood 112 (2008), 4250–4258.
185. Reiner, A., Heldt, S.A., Presley, C.S., Guley, N.H., Elberger, A.J., Deng, Y., D'Surney, L., Rogers, J.T., Ferrell, J., Bu, W., et al. Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189. Int. J. Mol. Sci. 16 (2015), 758–787.
186. Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G.P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E., Vassilopoulos, D., Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol. Scand. 119 (2009), 332–337.
187. Ricote, M., Glass, C.K., PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 1771 (2007), 926–935.
188. Rodriguez, M., Alvarez-Erviti, L., Blesa, F.J., Rodriguez-Oroz, M.C., Arina, A., Melero, I., Ramos, L.I., Obeso, J.A., Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol. Dis. 28 (2007), 316–325.
189. Rojo, A.I., Innamorato, N.G., Martin-Moreno, A.M., De Ceballos, M.L., Yamamoto, M., Cuadrado, A., Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58 (2010), 588–598.
190. Romero, J., Garcia-Palomero, E., Fernandez-Ruiz, J.J., Ramos, J.A., Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav. Pharmacol. 7 (1996), 299–302.
191. Rowin, J., Thiruppathi, M., Arhebamen, E., Sheng, J., Prabhakar, B.S., Meriggioli, M.N., Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve 46 (2012), 449–453.
192. Ruland, J., Return to homeostasis: downregulation of NF-kappaB responses. Nat. Immunol. 12 (2011), 709–714.
193. Sanchez-Guajardo, V., Febbraro, F., Kirik, D., Romero-Ramos, M., Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One, 5, 2010, e8784.
194. Sanchez-Guajardo, V., Barnum, C.J., Tansey, M.G., Romero-Ramos, M., Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5 (2013), 113–139.
195. Sanchez-Pernaute, R., Ferree, A., Cooper, O., Yu, M., Brownell, A.L., Isacson, O., Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation, 1, 2004, 6.
196. Satoh, N., Shimatsu, A., Himeno, A., Sasaki, Y., Yamakage, H., Yamada, K., Suganami, T., Ogawa, Y., Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care, 33, 2010, e7.
197. Schintu, N., Frau, L., Ibba, M., Garau, A., Carboni, E., Carta, A.R., Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox. Res. 16 (2009), 127–139.
198. Sheng, J.R., Muthusamy, T., Prabhakar, B.S., Meriggioli, M.N., GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J. Neuroimmunol. 240–241 (2011), 65–73.
199. Shi, M., Bradner, J., Hancock, A.M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., Jankovic, J., Zabetian, C.P., Kim, H.M., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69 (2011), 570–580.
200. Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P., Crossman, A.R., Brotchie, J.M., Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001), 2108–2111.
201. Smeyne, R.J., Jackson-Lewis, V., The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 134 (2005), 57–66.
202. Sriram, K., Matheson, J.M., Benkovic, S.A., Miller, D.B., Luster, M.I., O'Callaghan, J.P., Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16 (2002), 1474–1476.
203. Stout, R.D., Jiang, C., Matta, B., Tietzel, I., Watkins, S.K., Suttles, J., Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175 (2005), 342–349.
204. Straus, D.S., Glass, C.K., Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28 (2007), 551–558.
205. Su, X., Maguire-Zeiss, K.A., Giuliano, R., Prifti, L., Venkatesh, K., Federoff, H.J., Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 29 (2008), 1690–1701.
206. Swanson, C.R., Joers, V., Bondarenko, V., Brunner, K., Simmons, H.A., Ziegler, T.E., Kemnitz, J.W., Johnson, J.A., Emborg, M.E., The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflammation, 8, 2011, 91.
207. Szanto, A., Balint, B.L., Nagy, Z.S., Barta, E., Dezso, B., Pap, A., Szeles, L., Poliska, S., Oros, M., Evans, R.M., et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity 33 (2010), 699–712.
208. Tanaka, S., Ishii, A., Ohtaki, H., Shioda, S., Yoshida, T., Numazawa, S., Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice. J. Neuroinflammation, 10, 2013, 143.
209. Tang, Y., Le, W., Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol., 2015.
210. Tansey, M.G., Goldberg, M.S., Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37 (2010), 510–518.
211. Thomas, M., Le, W.D., Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr. Pharm. Des. 10 (2004), 679–686.
212. Tran, T.A., McCoy, M.K., Sporn, M.B., Tansey, M.G., The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J. Neuroinflammation, 5, 2008, 14.
213. Van der Perren, A., Toelen, J., Casteels, C., Macchi, F., Van Rompuy, A.S., Sarre, S., Casadei, N., Nuber, S., Himmelreich, U., Osorio Garcia, M.I., et al. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiol. Aging 36 (2015), 1543–1558.
214. Varga, T., Czimmerer, Z., Nagy, L., PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim. Biophys. Acta 1812 (2011), 1007–1022.
215. Vawter, M.P., Dillon-Carter, O., Tourtellotte, W.W., Carvey, P., Freed, W.J., TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp. Neurol. 142 (1996), 313–322.
216. Vazquez-Claverie, M., Garrido-Gil, P., San Sebastian, W., Izal-Azcarate, A., Belzunegui, S., Marcilla, I., Lopez, B., Luquin, M.R., Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J. Neuropathol. Exp. Neurol. 68 (2009), 977–984.
217. Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., Kanbe, D., Muramatsu, S., Kobayashi, K., Iwatsubo, T., Yoshimoto, M., Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 29 (2008), 574–585.
218. Walsh, S., Finn, D.P., Dowd, E., Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 175 (2011), 251–261.
219. Watson, M.B., Richter, F., Lee, S.K., Gabby, L., Wu, J., Masliah, E., Effros, R.B., Chesselet, M.F., Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp. Neurol. 237 (2012), 318–334.
220. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., Dawson, T.M., Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 16842–16847.
221. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.K., Ischiropoulos, H., Przedborski, S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002), 1763–1771.
222. Yamada, M., Iwatsubo, T., Mizuno, Y., Mochizuki, H., Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 91 (2004), 451–461.
223. Yasuda, Y., Shinagawa, R., Yamada, M., Mori, T., Tateishi, N., Fujita, S., Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 1138 (2007), 196–202.
224. Yasuda, Y., Shimoda, T., Uno, K., Tateishi, N., Furuya, S., Yagi, K., Suzuki, K., Fujita, S., The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J. Neuroimmunol. 204 (2008), 43–51.
225. Yoder, K.K., Nho, K., Risacher, S.L., Kim, S., Shen, L., Saykin, A.J., Influence of TSPO genotype on 11C-PBR28 standardized uptake values. J. Nucl. Med. 54 (2013), 1320–1322.
226. Zhang, W., Wang, J., Zhang, Y., Yuan, Y., Guan, W., Jin, C., Chen, H., Wang, X., Yang, X., He, F., The scaffold protein TANK/I-TRAF inhibits NF-kappaB activation by recruiting polo-like kinase 1. Mol. Biol. Cell 21 (2010), 2500–2513.
227. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004), 601–607.